Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
Leukemia|December 14, 2018
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosisNoemi Puig, Bruno Paiva, Marta Lasa, et al.
Blood Advances|March 19, 2026
Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO studyIrene Dogliotti, Cristina Jiménez, Veronica Peri, et al.
Hemasphere|April 25, 2025
High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapyAndrea Manubens, Bruno Paiva, Norma C Gutiérrez, et al.
Blood|June 16, 2021
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell developmentDaniel Alameda, Ibai Goicoechea, Marco Vicari, et al.
Haematologica|July 11, 2024
Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trialNoemí Puig, Cristina Agulló, Teresa Contreras, et al.
Blood Cancer Journal|March 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myelomaShaji Kumar, Sundar Jagannath, Katja C Weisel, et al.
Blood Cancer Journal|May 22, 2021
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trialNoemi Puig, Miguel T Hernández, Laura Rosiñol, et al.
Blood|June 11, 2025
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trialJuan-Jose Lahuerta, Jesús F San-Miguel, Ana Jiménez-Ubieto, et al.
The Lancet. Oncology|September 23, 2014
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trialJesús F San-Miguel, Vânia T M Hungria, Sung-Soo Yoon, et al.
Blood Cancer Journal|April 20, 2022
A simple score to predict early severe infections in patients with newly diagnosed multiple myelomaCristina Encinas, José-Ángel Hernandez-Rivas, Albert Oriol, et al.
Pageof 13